Article in Blood cancer journal, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
1 citing paper in PubMed.
Frontiers in cell and developmental biology · 2017
Review
4 · The record
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
6 authors.
K LamMoores UCSD Cancer Center, University of California, San Diego, La Jolla, CA, USA.
A MuselmanDivison of Biological Sciences, University of California, San Diego, La Jolla, CA, USA.
R DuDivison of Biological Sciences, University of California, San Diego, La Jolla, CA, USA.
M YanMoores UCSD Cancer Center, University of California, San Diego, La Jolla, CA, USA.
S MatsuuraMoores UCSD Cancer Center, University of California, San Diego, La Jolla, CA, USA.
D-E ZhangMoores UCSD Cancer Center, University of California, San Diego, La Jolla, CA, USA.
Funding
MEDICAL SCIENTIST TRAINING PROGRAMT32GM007198 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI CHI, NEIL C, INSEL, PAUL A · 1985 to 2024
$29.3M
Synergestic roles of SRSF2 and RUNX1 in blood cell development and pathologyR01DK098808 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ZHANG, DONG-ER · 2013 to 2022
$4.8M
Combinatorial Profiling and Characterization of AML1 Function in HematopoiesisF30HL103106 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI LAM, KENTSON · 2011 to 2014
$159k
Novel molecular targets of RUNX in hematopoietic stem/progenitor cellsF32HL091641 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI MATSUURA, SHINOBU · 2008 to 2010
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Loss of RUNX1 function results in enhanced granulocyte-colony-stimulating factor-mediated mobilization. · full record | OpenQuestion